HLF
Herbalife Ltd. Health Care Wholesale-Drugs, Proprietaries & Druggists' Sundries Russell 3000
$13.05Close
$1.3BMarket cap
$7.75 – $19.9652-week range
Nov 2, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Far from its high 35% below its 52-week high
- Earnings shrinking EPS −153% year on year
- Results soon Nov 2, 2026, in 1 day
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
down 2.5%
price change
1mo
up 7.6%
price change
12-month return
up 68%
market up 11% ·
its own up 52%
F-score
5 / 9
Mixed
Altman Z″
0.63
Elevated risk
P/E
5.9×
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 16.2%
EBIT / enterprise value
Cheaper than
97%
of the market · markedly cheap
Revenue growth
up 1%
year on year
EPS growth
down 153%
latest quarter · -169 pts
Sales growth
up 5%
latest quarter · -2 pts
ROE
—
return on equity
Free cash margin
up 5%
$252.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
2.7×
Interest cover
2.2×EBIT / interest
Piotroski tests
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profits backed by cash
- short-term liquidity improved
- assets working harder
Repair signals
- Revenue reaccelerating (-1% then +1%)
Trade setup
ATR%
3.9%
$0.50 a day · 2×ATR $12.04
RS
52 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.43
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 2 of 8
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$515.1M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.1% over the year, from 101m to 103m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Last shock
Aug 31, 2026-12% in one session3.4× volumeon an SEC filing+19% since
Financials
- Gross 78%
- Net 5%
- Free cash 5%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.5B | $5.8B | $5.2B | $5.1B | $5.0B | $5.0B |
| Gross margin | 79% | 79% | 77% | 76% | 78% | 78% |
| Operating income | $640.6M | $734.1M | $545.2M | $356.4M | $385.9M | $481.0M |
| Net income | $372.6M | $447.2M | $321.3M | $142.2M | $254.3M | $228.3M |
| Net margin | 7% | 8% | 6% | 3% | 5% | 5% |
| Earnings per share | $2.77 | $4.13 | $3.23 | $1.42 | $2.50 | $2.20 |
| Free cash flow | $516.6M | $308.9M | $196.1M | $222.5M | $163.4M | $252.9M |
| Free cash margin | 9% | 5% | 4% | 4% | 3% | 5% |
| Cash | $1.0B | $601.5M | $508.0M | $575.2M | $415.3M | $353.1M |
| Long-term debt | $2.4B | $2.7B | $2.7B | $2.3B | $2.0B | $2.0B |
| Shareholders' equity | -$856.1M | -$1.4B | -$1.3B | -$1.1B | -$801.1M | -$515.1M |
| Shares outstanding | 120.10m | 100.80m | 97.90m | 99.20m | 101.20m | 103.30m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 18, 2026 | Annual ↗ | Dec 31, 2025 | 49d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| Apr 30, 2025 | Quarterly ↗ | Mar 31, 2025 | 30d |
| Feb 19, 2025 | Annual ↗ | Dec 31, 2024 | 50d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Feb 14, 2024 | Annual ↗ | Dec 31, 2023 | 45d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 31, 2026 | Director or officer change ↗ |
| Aug 5, 2026 | Results · Director or officer change · Regulation FD ↗ |
| May 6, 2026 | Results · Shareholder vote · Regulation FD ↗ |
| May 1, 2026 | Material agreement · New obligation · Obligation accelerated · Other events ↗ |
| Apr 16, 2026 | Other events ↗ |
| Apr 14, 2026 | Results · Other events ↗ |
| Feb 18, 2026 | Results · Regulation FD ↗ |
| Nov 5, 2025 | Results · Regulation FD ↗ |
| Aug 6, 2025 | Results · Regulation FD ↗ |
| Jun 16, 2025 | Other events ↗ |
| Apr 30, 2025 | Results · Regulation FD ↗ |
| Apr 25, 2025 | Shareholder vote ↗ |